{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:32Z","timestamp":1793405312101,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T13:46:43Z","timestamp":1725630403000},"page":"865-869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Ismail A.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rem Ehab","family":"Abdelkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hosney","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-2046","authenticated-orcid":false,"given":"George","family":"Hanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghena","family":"Shahwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Meshref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-4119","authenticated-orcid":false,"given":"Abdulqadir J.","family":"Nashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.009_bib0001","series-title":"GeneReviews\u00ae","article-title":"Neurofibromatosis 1","author":"Friedman","year":"1993"},{"issue":"1","key":"10.1016\/j.clinthera.2024.08.009_bib0002","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and prevalence of neurofibromatosis Type 1 and 2: a systematic review and meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2024.08.009_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis Type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0004","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1469-8749.2012.04377.x","article-title":"The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis Type 1","volume":"54","author":"Lidzba","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0005","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1542\/peds.2013-1868","article-title":"Neurofibromatosis Type 1 and autism spectrum disorder","volume":"132","author":"Garg","year":"2013","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.clinthera.2024.08.009_bib0006","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.3390\/ijms22115850","article-title":"Current understanding of neurofibromatosis Type 1, 2, and schwannomatosis","volume":"22","author":"Tamura","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clinthera.2024.08.009_bib0007","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/13543784.2023.2263836","article-title":"NF1 alterations in cancers: therapeutic implications in precision medicine","volume":"32","author":"Giraud","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.clinthera.2024.08.009_bib0008","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.clinthera.2024.08.009_bib0009","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"9637","key":"10.1016\/j.clinthera.2024.08.009_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12051201","article-title":"mTOR pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with everolimus","volume":"12","author":"Gelsomino","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clinthera.2024.08.009_bib0012","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","article-title":"Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors","volume":"7","author":"Johansson","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.clinthera.2024.08.009_bib0013","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","article-title":"Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial","volume":"139","author":"Zehou","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.clinthera.2024.08.009_bib0014","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","article-title":"Treatment of disfiguring cutaneous lesions in neurofibromatosis-1 with everolimus: a phase II, open-label, single-arm trial","volume":"18","author":"Slopis","year":"2018","journal-title":"Drugs RD"},{"issue":"4","key":"10.1016\/j.clinthera.2024.08.009_bib0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.clinthera.2024.08.009_bib0017","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis Type 1-associated pediatric low-grade glioma: a neurofibromatosis clinical trials consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0018","unstructured":"ROBINS-I tool | Cochrane Methods. https:\/\/methods.cochrane.org\/robins-i. Accessed on September 3, 2024."},{"issue":"7","key":"10.1016\/j.clinthera.2024.08.009_bib0019","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.21037\/jtd-21-195","article-title":"A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations","volume":"13","author":"Devarakonda","year":"2021","journal-title":"J Thorac Dis"},{"issue":"1","key":"10.1016\/j.clinthera.2024.08.009_bib0020","first-page":"1","article-title":"Clinical and genetic aspects of neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0021","first-page":"1","article-title":"Impacts of NF1 gene mutations and genetic modifiers in neurofibromatosis Type 1","volume":"12","author":"Wang","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.clinthera.2024.08.009_bib0022","first-page":"55","article-title":"Natural history and disease burden of neurofibromatosis Type 1 with plexiform neurofibromas: a systematic literature review","volume":"12","author":"Copley-Merriman","year":"2021","journal-title":"Adolesc Health Med Ther"},{"issue":"4","key":"10.1016\/j.clinthera.2024.08.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100223","article-title":"Novel molecular targeted therapies for patients with neurofibromatosis Type 1 with inoperable plexiform neurofibromas: a comprehensive review","volume":"6","author":"Solares","year":"2021","journal-title":"ESMO Open"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T21:13:41Z","timestamp":1732742021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0149291824002200"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}